INTRODUCTION
============

Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that is clinically used for anesthesia. In contrast to other anesthetics, ketamine raises blood pressure at clinical concentrations \[[@B1][@B2][@B3][@B4][@B5]\]. This unique characteristic of ketamine makes it useful for patients at risk for shock due to severe hemorrhage or hypotension. However, the use of ketamine in patients with hypertension or coronary disease is contraindicated \[[@B4][@B6]\]. Although ketamine-induced hypertension is largely known to occur through the inhibition of catecholamine reuptake in the sympathetic nervous system, its mechanism is not completely understood thus far \[[@B1][@B2]\].

To study ketamine-induced hypertension, several previous studies examined the hypothesis that ketamine contracts arteries to increase peripheral vascular resistance. However, these previous *ex vivo* and *in vitro* studies reported that ketamine has a vasodilatory effect on isolated arteries or smooth muscle cells \[[@B7][@B8][@B9][@B10][@B11]\]. An important point to be considered when interpreting these results is that most of these studies evaluated the direct *ex vivo* effect of ketamine on arteries after pre-contraction with high concentrations of vasoconstrictors such as KCl or norepinephrine (NE) \[[@B7]\].

It was also reported that the psychogenic effects of NMDA receptor antagonists such as ketamine, MK-801, and phencyclidine seem to go beyond the inhibition of the NMDA receptor; both dopamine D~2~ and serotonin 5-HT~2~ receptors are reportedly related to the pathogenesis of schizophrenia, and the agonistic effects of ketamine on D~2~ receptors and 5-HT~2~ receptors have been reported \[[@B12][@B13][@B14]\]. Because the 5-HT~2A~ receptor is a major subtype found in peripheral arteries, ketamine can act as a vasoconstrictor, provided that it can activate the 5-HT~2A~ receptor in a clinical setting (i.e., in the presence of resting concentrations of 5-HT, which were reported to be \~100 nM \[[@B15]\]).

Here, we re-examined the direct effect of ketamine on the isolated arterial mechanics under physiological conditions, in the presence of physiological resting concentrations of vasoactive agonists such as 5-HT and NE. We found that ketamine is a vasoconstrictor in the presence of physiological concentrations of 5-HT, because of the facilitating effect of ketamine on the activation of serotonin 5-HT~2A~ receptors. We expect that these results will contribute to interpreting the hypertensive effect of ketamine in a clinical setting. Furthermore, the results of this study could provide valuable insight into interpreting the pathogenesis of schizophrenia, since over-activity of 5-HT~2A~ receptors may play a role and ketamine is used for animal models of the disorder \[[@B12][@B13][@B14]\].

METHODS
=======

Animals and tissue preparations
-------------------------------

All experiments were conducted in accordance with the National Institutes of Health guidelines for the care and use of animals. The Institutional Animal Care and Use Committee of Konkuk University approved this study. Mesenteric arterial rings were prepared as previously described \[[@B16]\]. Male Sprague-Dawley (SD) rats (10- to 11-week-old) were exsanguinated by cutting the carotid arteries under deep ketamine-xylazine anesthesia or after exposure to rising concentrations of carbon dioxide. The branches of the superior mesenteric arteries were promptly isolated and placed in physiological saline solutions (PSS) containing 136.9 mM NaCl, 5.4 mM KCl, 1.5 mM CaCl~2~, 1.0 mM MgCl~2~, 23.8 mM NaHCO~3~, 1.2 mM NaH~2~PO~4~, 0.01 mM EDTA, and 5.5 mM glucose. The arteries were carefully cleaned of fat and connective tissue under a stereomicroscope and prepared as rings (3.5 mm in length) for tension measurements. The endothelium was mechanically removed with fine stainless-steel wire \[[@B17]\]. Endothelial removal was confirmed by the absence of relaxation induced by acetylcholine (10 µM) after contraction by NE (1\~10 µM) or 5 HT (1\~10 µM).

Tension measurements
--------------------

The isometric tension of arterial rings was measured as previously described \[[@B16]\]. The arterial rings were mounted vertically on two L-shaped stainless steel wires in a 3 mL tissue chamber. One wire was attached to a micromanipulator and the other to an isometric force transducer (FT03; Grass, West Warwick, RI, USA). Changes in isometric force were digitally acquired at 1 Hz with a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO, USA). Resting tension was set to 1 g by the micromanipulator. After equilibration for 60 min under resting tension in a tissue chamber filled with PSS, the rings were sequentially exposed to 70 mM KCl PSS (10 min) and PSS (15 min) three times for stabilization. The high KCl (70 mM) PSS was prepared by replacing NaCl with equimolar KCl in PSS. Bathing solutions were thermostatically controlled at 37℃ and were continuously saturated with a mixture of 95% O~2~ and 5% CO~2~ to achieve pH 7.4.

Drugs
-----

Ketanserin, anpirtoline, and BW723C86 were purchased from Tocris (Bristol, UK). All other chemicals, including ketamine racemate, were purchased from Sigma-Aldrich (St. Louis, MO, USA). The ketamine, NE, 5-HT, and acetylcholine were prepared as stock solutions in distilled water. The drugs were diluted in the bathing solution on the day of the experiment.

Statistical analysis
--------------------

The results are shown as the mean±S.E.M. Paired or independent Student\'s *t*-tests were used to test for significance, as appropriate. p values\<0.05 were deemed statistically significant.

RESULTS
=======

Effect of ketamine on the tone of arterial rings in the presence and absence of physiological concentrations of 5-HT and NE
---------------------------------------------------------------------------------------------------------------------------

Plasma concentrations of 5-HT were reported to be between 30 and 150 nM \[[@B15]\], which are the subthreshold concentrations of 5-HT required for contraction of rat mesenteric arteries \[[@B18][@B19]\]. The threshold for 5-HT-induced mesenteric arterial contraction was \~300 nM \[[@B19]\]. To examine the effect of ketamine on vascular tone in the presence of physiological concentrations of 5-HT, ketamine was administered in the presence of 100\~200 nM 5-HT. [Fig. 1A](#F1){ref-type="fig"} (upper panel) shows a typical representative trace: in the presence of physiological low concentration (100\~200 nM) of 5-HT, administration of ketamine (10\~100 µM) contracted the arterial rings. The lower panel of [Fig. 1A](#F1){ref-type="fig"} summarizes the effect of ketamine on the tone of arterial rings in the presence of 100\~200 nM 5-HT. In the presence of a physiological low concentration (10 nM) of NE, ketamine did not contract the arterial rings ([Fig. 1B](#F1){ref-type="fig"}). On the contrary, a high concentration (300 µM) of ketamine dilated the arterial rings that were slightly pre-contracted with NE (10 nM, [Fig. 1B](#F1){ref-type="fig"}). Ketamine had no effect on the resting tone of the mesenteric arterial rings in the absence of vasoactive agonists such as 5-HT and NE ([Fig. 1C](#F1){ref-type="fig"}).

Effect of ketamine on the concentration-contraction relationship of 5-HT and NE
-------------------------------------------------------------------------------

As seen in [Fig. 1A](#F1){ref-type="fig"}, 30 µM ketamine induced maximal vasoconstriction in the presence of physiological concentrations of 5-HT. To further examine the mechanism by which ketamine contracted the arterial rings in the presence of low concentrations of 5-HT, we compared the concentration-response (contraction) curve (CRC) of 5-HT in the absence and presence of ketamine (30 µM); note that the maximal constrictive effect of ketamine in the presence of 5-HT occurred at 30 µM ketamine. As shown in [Fig. 2A](#F2){ref-type="fig"}, ketamine (30 µM) markedly shifted the CRC of 5-HT to the left, with little effect on the maximal contraction. Although pretreatment with a high concentration (300 µM) of ketamine decreased the maximal contraction induced by 5-HT , the shift of the CRC to the left by ketamine was still evident ([Fig. 2B](#F2){ref-type="fig"}). Contrary to the ketamine-induced shift to the left of the 5-HT CRC, 30 µM ketamine had no effect on the CRC of NE ([Fig. 2C](#F2){ref-type="fig"}). A high concentration of ketamine (300 µM) decreased the CRC in the presence of various concentrations of NE without shifting the NE CRC ([Fig. 2D](#F2){ref-type="fig"}).

Facilitation of 5-HT~2A~ receptor activation by ketamine
--------------------------------------------------------

It was reported that the 5-HT~2A~ receptor is responsible for 5-HT-induced vasoconstriction of control rat mesenteric arteries \[[@B18][@B19]\]. In the case of hypertensive arteries, the unmasking or up-regulation of 5-HT~1B~ or 5-HT~2B~ receptors was reported to contribute to the enhancement in the 5-HT-inudced vasoconstriction \[[@B18]\]. Therefore, we examined whether ketamine facilitated the activation of the 5-HT~2A~ receptor or whether ketamine unmasked the silent 5-HT~1B~ or 5-HT~2B~ receptor to selectively increase the 5-HT-induced vasoconstriction (left shift of 5-HT CRC) without having an effect on the NE-induced vasoconstriction ([Figs. 2A and C](#F2){ref-type="fig"}). A previous study reported that the 5-HT~2A~ receptor mediated the 5-HT-induced contraction of rat mesenteric artery \[[@B19]\]; in our study, the 5-HT CRC was markedly shifted to the right by ketanserine (10 nM, [Fig. 3A](#F3){ref-type="fig"}, open symbols), which is a potent competitive inhibitor of the 5-HT~2A~ receptor. Ketanserine also similarly shifted the 5-HT CRC in the presence of ketamine (30 µM, [Fig. 3A](#F3){ref-type="fig"}, filled symbols). These results indicate that ketamine shifted the 5-HT CRC to the left ([Fig. 2A](#F2){ref-type="fig"}) by acting on the 5-HT~2A~ receptor.

Furthermore, we examined the hypothesis that ketamine unmasked 5-HT~1B~ or 5-HT~2B~ receptors to increase the 5-HT-induced vasoconstriction. However, anpirtoline and BW723C86, the agonists for 5-HT~1B~ and 5-HT~2B~ receptors, respectively, failed to contract rat mesenteric arterial rings both in the absence and in the presence of ketamine ([Fig. 3C](#F3){ref-type="fig"}). This indicates that ketamine did not unmask 5-HT~1B~ and 5-HT~2B~ receptors in the rat mesenteric artery.

DISCUSSION
==========

The major finding of this study is that clinical concentrations of ketamine (10\~100 µM) contract rat mesenteric arteries in the presence of physiological plasma concentrations of 5-HT. These results may explain the previous paradoxical *ex vivo* or *in vitro* vasodilatory actions of ketamine in spite of its *in vivo* hypertensive effect. Although the effects of ketamine on the sympathetic nervous system (i.e., inhibition of catecholamine reuptake) may be a primary mechanism for the systemic hypertensive effect of ketamine, this study clearly demonstrated that the direct effect of ketamine on arteries is not vasodilatory but vasoconstrictive in a physiological clinical setting: ketamine was not vasoconstrictive by itself ([Fig. 1C](#F1){ref-type="fig"}), however, 5-HT at its basal plasma concentration renders ketamine \"practically vasoconstrictive\".

Ketamine constricts arteries in a clinical setting
--------------------------------------------------

As noted above, previous *ex vivo* or *in vitro* studies reported the vasodilatory actions of ketamine. The vasodilatory effect of ketamine was reported to involve inhibition of both influx of Ca^2+^ from extracellular space and release of Ca^2+^ from intracellular Ca^2+^ stores \[[@B7][@B8][@B9][@B10][@B11]\]. However, the vasodilatory actions of ketamine were usually observed at concentrations above 300 µM, which is higher than the clinical plasma concentrations of ketamine \[[@B20]\]. Moreover, this effect was observed after precontraction by high concentrations (1\~10 µM) of NE or high concentrations (40\~70 mM) of KCl; these high concentrations are not likely to be maintained for a significant duration in a clinical setting \[[@B7][@B16]\]. In this study, we aimed to examine the effect of ketamine in more clinically relevant, physiological conditions (in the presence of sub-micromolar concentrations of 5-HT or NE) than those employed in previous studies. We found that ketamine is vasoconstrictive under these conditions because of its facilitative effect on the activation of 5-HT~2A~ receptors. Moreover, the vasoconstrictive action of ketamine through the 5-HT~2A~ receptor was most dominant at the concentration of 30 µM; this concentration is in the clinical range \[[@B20]\].

Selective facilitation of 5-HT~2A~ receptor activation by ketamine
------------------------------------------------------------------

In the normal rat aorta and mesenteric artery, the 5-HT~2A~ receptor is a primary 5-HT receptor subtype \[[@B19][@B21]\], and 5-HT~1B~ or 5-HT~2B~ receptors can be upregulated or unmasked under conditions such as hypertension \[[@B18]\] and increased pre-vasocontraction with depolarization \[[@B22]\]. Because ketamine reportedly blocked voltage-gated K^+^ channels and depolarized the membrane potential of vascular myocytes \[[@B23]\] (which is interestingly also the mechanism of 5-HT-induced vasoconstriction \[[@B24][@B25]\]), depolarization by pre-treatment with ketamine could unmask the 5-HT~1B~ or 5-HT~2B~ receptors \[[@B22]\]. The results of the present study, however, clearly demonstrate that ketamine selectively facilitated the activation of 5-HT~2A~ receptors without unmasking 5-HT~1B~ or 5-HT~2B~ receptors in rat mesenteric arteries. This is supported by the following evidence: First, ketanserin, a potent and selective inhibitor of 5-HT~2A~ receptors, reversed the facilitative (left-shifting) effect of ketamine on the CRC of 5-HT ([Fig. 3A](#F3){ref-type="fig"}); second, anpirtoline and BW723C86 failed to contract the mesenteric arterial rings both in the absence and presence of ketamine, which indicates that other 5-HT receptor subtypes such as 5-HT~1B~ and 5-HT~2B~ were not involved in the increased vasoconstriction of 5-HT by ketamine; third, vasoconstriction by NE through the adrenergic receptor was not affected by ketamine. The primary receptor subtype for NE-induced vasoconstriction of the rat mesenteric artery was reported to be the adrenergic α~1D~ receptor \[[@B26][@B27][@B28]\], and the results of the present study indicate that ketamine did not affect the sensitivity of the adrenergic α~1D~ receptor. The NE CRC was not affected by 30 µM ketamine ([Fig. 2C](#F2){ref-type="fig"}). Considering that the 5-HT~2A~ and adrenergic α~1D~ receptors are similar Gq11 protein coupled receptors (GqPCR) and they share similar signaling pathways (including activation of phospholipase Cβ), it is expected that ketamine selectively and directly interacts with the 5-HT~2A~ receptor without interacting with the downstream signaling cascade. Interestingly, the direct interaction of ketamine with dopamine D~2~ and 5-HT~2~ receptors was previously reported \[[@B12]\]. Involvement of NMDA receptors in the vasoconstrictive actions of ketamine can also be excluded because the rat mesenteric artery lacks functional NMDA receptors \[[@B16]\].

Mechanism of ketamine-induced facilitation of 5-HT~2A~ receptors
----------------------------------------------------------------

In this study, data for elucidating the mechanism of the ketamine-induced facilitation of 5-HT~2A~ receptors were not provided. In our previous study, however, we reported that activation of src tyrosine kinase and subsequent inhibition of Kv channels are the mechanisms of 5-HT-induced vasoconstriction in rat mesenteric arteries \[[@B19]\]. Therefore, ketamine might have amplified src activation after 5-HT~2A~ receptor activation. Another possibility is that ketamine augmented the inhibition of Kv channels after 5-HT~2A~ receptor and subsequent src activation because ketamine itself blocks Kv channels in mesenteric arteries \[[@B23]\]. Because this mechanism warrants further investigation, we are planning a study to elucidate the mechanism of the ketamine-induced facilitation of 5-HT~2A~ receptors. Our preliminary observation is that ketamine increases the phosphorylation of src in the presence of low concentrations of 5-HT (\~30 nM), which suggests that ketamine may facilitate the src activation process after 5-HT~2A~ receptor activation. It is also interesting that some selective serotonin reuptake inhibitors (SSRIs), which are frequently used for treating mood disorders and work by increasing 5-HT concentrations in the synaptic spaces of the central nervous system, are reported to block Kv channels, such as Kv1.5 \[[@B29][@B30]\], which are the downstream targets of 5-HT~2A~ receptors \[[@B19][@B25]\].

Further clinical implications
-----------------------------

In this study, the vasoconstrictive action of ketamine in arteries through the enhancement of the activation of 5-HT~2A~ receptors was reported for the first time. However, in the central nervous system, interaction of ketamine and other structurally-related non-competitive inhibitors of NMDA receptors (such as MK801 and phencyclidine) with 5-HT~2A~ receptors was previously reported \[[@B12][@B13][@B14]\]. Moreover, several studies suggested that the direct interaction of ketamine and phencyclidine with 5-HT~2A~ receptors is involved in the pathogenesis of schizophrenia by enhancing the activity of 5-HT~2A~ receptors. In this regard, the results of the present study again strengthen the hypothesis that ketamine facilitates 5-HT~2A~ receptor activation. The mechanism and clinical significance of the interaction of phencyclidine analogs, ketamine, MK801, and phencyclidine with 5-HT~2A~ receptors warrant further study.
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![Effects of ketamine on the tone of arterial rings in the absence and presence of 5-hydroxytryptamine (5-HT) or norepinephrine (NE).\
(A) Upper panel represents a typical trace showing the effect of ketamine on the arterial tone in the presence of 5-HT (200 nM). Lower panel summarizes the effect of ketamine on the arterial tone in the presence of 5-HT (100\~200 nM). (B) Upper panel represents a typical trace showing the effect of ketamine on the arterial tone in the presence of NE (10 nM). Lower panel summarizes the upper panel experiments. (C) Upper panel represents a typical trace showing the effect of ketamine on the arterial tone in the absence of 5-HT and NE. Lower panel summarizes the upper panel experiments.](kjpp-20-605-g001){#F1}

![Effect of ketamine on the concentration-response (contraction) curve (CRC) of 5-HT and NE.\
(A, B) CRCs of 5-HT in the absence and presence of 30 and 300 µM ketamine, respectively. (C, D) CRCs of NE in the absence and presence of 30 and 300 µM ketamine, respectively.](kjpp-20-605-g002){#F2}

![Effects of ketanserin, anpirtoline, and BW723C86 on the ketamine-induced facilitation of vasoconstriction.\
(A) Ketanserine, a potent competitive inhibitor of 5-HT~2A~ receptors, similarly shifted the CRCs of 5-HT in the absence and presence of ketamine (30 µM). (B) Anpirtoline and BW723C86, which are agonists of 5-HT~1B~ and 5-HT~2B~ receptors, respectively, failed to contract the mesenteric arterial rings both in the presence and in the absence of ketamine (30 µM).](kjpp-20-605-g003){#F3}
